Hos patienter med lavt baselineniveau for hæmoglobin før indledning af terapi findes en forhøjet risiko for anæmi under behandling med rosiglitazon.
In patients with low haemoglobin levels before initiating therapy, there is an increased risk of anaemia during treatment with rosiglitazone.